COMPANY
Alnylam Pharmaceuticals
FDA-approved therapeutic company Clinical Phase 3
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Senior Manager, HCP Marketing, US Congress Lead | United States | Oct 22, 2026 | Oct 23, 2026 |
| Principal Scientist, Biotransformation and Metabolite Profiling | United States | Oct 21, 2026 | Oct 22, 2026 |
| Senior Director, Commercial Operations | Cambridge, MA | Oct 21, 2026 | Oct 22, 2026 |
| Manager, Global Patient Safety & Risk Mgmnt | Cambridge, MA | Oct 16, 2026 | Oct 17, 2026 |
| Associate Director, Identity & Access Management Architect | Cambridge, MA | Oct 15, 2026 | Oct 16, 2026 |
Trial and FDA signals
- New trial + clinical hiring Started a Phase 2 trial (NCT07636811, actual start Aug 17, 2026) (+1 other new trial); since then posted 18 clinical-operations roles. ClinicalTrials.gov NCT07636811 (Aug 17, 2026)
Evidence (2 events)
- Aug 17, 2026 · ClinicalTrials.gov NCT07636811
leadSponsor.name='Alnylam Pharmaceuticals'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-08-17,type:ACTUAL}; studyFirstPostDate=2026-06-09; briefTitle="A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)" - Jul 30, 2026 · ClinicalTrials.gov NCT07575308
leadSponsor.name='Alnylam Pharmaceuticals'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-07-30,type:ACTUAL}; studyFirstPostDate=2026-05-08; briefTitle='HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB'
- Aug 17, 2026 · ClinicalTrials.gov NCT07636811
Timeline
- Trial start Phase 2: A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD) source ↗
- Trial start 2: HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB source ↗
- Trial start Phase 1: A Study to Evaluate ALN-6222 in Participants With Obesity source ↗
- Trial start Phase 2: A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran source ↗
- Trial start Phase 1/Phase 2: A Study to Evaluate ALN-2232 in Participants With Obesity source ↗
- Trial start Phase 1: A Study to Evaluate ALN-4915 in Adult Healthy Volunteers source ↗
- Trial start Phase 3: TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy source ↗
- Trial start Phase 2: A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus source ↗
- Trial start —: DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting source ↗
- Trial start Phase 1: A Study to Evaluate ALN-4285 in Adult Healthy Volunteers source ↗
- Debt Debt financing announced Dec 11, 2025. Source: SEC filing. source ↗
- Trial start Phase 1: A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease source ↗
- Trial start Phase 3: Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease source ↗
- Debt Debt: $575M (not counted as a raise), announced Sep 9, 2025. Source: SEC filing. source ↗
- Trial start Phase 3: TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy source ↗
- FDA FDA New indication / efficacy supplement: AMVUTTRA (vutrisiran sodium) — NDA215515/6, Mar 20, 2025. Applicant at approval: Alnylam Pharmaceuticals, Inc. source ↗
- Trial start Phase 1/Phase 2: A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM source ↗
- Trial start Phase 1: A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma source ↗
- Trial start Phase 3: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy source ↗
- Trial start Phase 1/Phase 2: A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT) source ↗
- Trial start Phase 1: A Study to Evaluate ALN-AGT01 RVR in Adult Healthy Volunteers source ↗
- Trial start Phase 1: A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease source ↗
- Trial start Phase 1/Phase 2: A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension source ↗
- Trial start 2: A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy source ↗
- Trial start —: Observational Study of Neurofilament Light Chain (NfL) as a Biomarker in Asymptomatic Carriers of the Transthyretin (TTR) Variants and Patients With Hereditary Transthyretin-mediated (hATTR) Amyloi source ↗
Upcoming milestones
- Dec 29, 2026 (ESTIMATED) · Phase 1 · A Study to Evaluate ALN-4285 in Adult Healthy Volunteers · NCT07295717
- Apr 27, 2027 (ESTIMATED) · Phase 1/Phase 2 · A Study to Evaluate ALN-2232 in Participants With Obesity · NCT07463846
- May 28, 2027 (ESTIMATED) · Phase 2 · A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus · NCT07465224
- Jun 30, 2027 (ESTIMATED) · 2 · HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB · NCT07575308
- Jul 31, 2027 (ESTIMATED) · Phase 1 · A Study to Evaluate ALN-4915 in Adult Healthy Volunteers · NCT07535606
- Aug 9, 2027 (ESTIMATED) · 2 · A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy · NCT06393712
- Aug 31, 2027 (ESTIMATED) · Phase 1/Phase 2 · A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM · NCT06845202
- Sep 30, 2027 (ESTIMATED) · Phase 1 · A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma · NCT06600321
Funding
Clinical trials (lead sponsor) Showing 50 of 84
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07358078 | DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting | Not listed | Recruiting | Jan 9, 2026 | Oct 23, 2030 (estimated) |
| NCT05040373 | Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program | Not listed | Recruiting | Aug 1, 2020 | Oct 12, 2030 (estimated) |
| NCT07214727 | A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease | Phase 1 | Recruiting | Oct 15, 2025 | Mar 6, 2030 (estimated) |
| NCT07223203 | TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy | Phase 3 | Recruiting | Feb 3, 2026 | Dec 27, 2027 (estimated) |
| NCT07553442 | A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran | Phase 2 | Recruiting | Apr 27, 2026 | Apr 1, 2028 (estimated) |
| NCT04982393 | BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1) | Not listed | Active, not recruiting | Dec 13, 2021 | Jan 2, 2029 (estimated) |
| NCT04883905 | ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP) | Not listed | Recruiting | Apr 26, 2021 | Dec 31, 2030 (estimated) |
| NCT07575308 | HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB | 2 | Recruiting | Jul 30, 2026 | Jun 30, 2027 (estimated) |
| NCT07181109 | Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease | Phase 3 | Recruiting | Sep 22, 2025 | Sep 23, 2030 (estimated) |
| NCT06393712 | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy | 2 | Active, not recruiting | May 17, 2024 | Aug 9, 2027 (estimated) |
| NCT07295717 | A Study to Evaluate ALN-4285 in Adult Healthy Volunteers | Phase 1 | Recruiting | Dec 12, 2025 | Dec 29, 2026 (estimated) |
| NCT07052903 | TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy | Phase 3 | Recruiting | Jul 2, 2025 | May 28, 2030 (estimated) |
| NCT07463846 | A Study to Evaluate ALN-2232 in Participants With Obesity | Phase 1/Phase 2 | Recruiting | Mar 2, 2026 | Apr 27, 2027 (estimated) |
| NCT07535606 | A Study to Evaluate ALN-4915 in Adult Healthy Volunteers | Phase 1 | Recruiting | Mar 2, 2026 | Jul 31, 2027 (estimated) |
| NCT07465224 | A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus | Phase 2 | Recruiting | Jan 15, 2026 | May 28, 2027 (estimated) |
| NCT06845202 | A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM | Phase 1/Phase 2 | Active, not recruiting | Mar 3, 2025 | Aug 31, 2027 (estimated) |
| NCT06659640 | A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT) | Phase 1/Phase 2 | Active, not recruiting | Nov 7, 2024 | Jan 5, 2028 (estimated) |
| NCT06585449 | A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease | Phase 1 | Recruiting | Oct 14, 2024 | Jul 5, 2028 (estimated) |
| NCT05231785 | A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD | Phase 1 | Recruiting | Feb 4, 2022 | Apr 20, 2029 (estimated) |
| NCT04561518 | ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) | Not listed | Recruiting | Nov 23, 2020 | Dec 31, 2033 (estimated) |
| NCT07636811 | A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD) | Phase 2 | Recruiting | Aug 17, 2026 | May 18, 2030 (estimated) |
| NCT07624071 | A Study to Evaluate ALN-6222 in Participants With Obesity | Phase 1 | Recruiting | Jun 4, 2026 | Dec 14, 2027 (estimated) |
| NCT06360289 | Observational Study of Neurofilament Light Chain (NfL) as a Biomarker in Asymptomatic Carriers of the Transthyretin (TTR) Variants and Patients With Hereditary Transthyretin-mediated (hATTR) Amyloidosis With Polyneuropathy | Not listed | Active, not recruiting | Apr 25, 2024 | Dec 15, 2027 (estimated) |
| NCT06600321 | A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma | Phase 1 | Recruiting | Dec 30, 2024 | Sep 30, 2027 (estimated) |
| NCT06423352 | A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension | Phase 1/Phase 2 | Completed | Jun 5, 2024 | Jul 17, 2025 (actual) |
| NCT03997383 | APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy) | Phase 3 | Completed | Sep 4, 2019 | Jun 20, 2022 (actual) |
| NCT06272487 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | Phase 2 | Completed | Feb 29, 2024 | Jun 19, 2025 (actual) |
| NCT06679946 | A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy | Phase 3 | Enrolling by invitation | Dec 3, 2024 | Mar 31, 2028 (estimated) |
| NCT05661916 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Subjects | Phase 1 | Completed | Jan 16, 2023 | Sep 30, 2025 (actual) |
| NCT04153149 | HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy | Phase 3 | Active, not recruiting | Nov 26, 2019 | May 8, 2024 (actual) |
| NCT03759379 | HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis) | Phase 3 | Completed | Feb 14, 2019 | Nov 10, 2020 (actual) |
| NCT04936035 | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension | Phase 2 | Completed | Jul 7, 2021 | Apr 4, 2023 (actual) |
| NCT05103332 | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | Phase 2 | Completed | Nov 5, 2021 | Dec 11, 2023 (actual) |
| NCT06675565 | A Study to Evaluate ALN-AGT01 RVR in Adult Healthy Volunteers | Phase 1 | Completed | Nov 5, 2024 | Sep 8, 2025 (actual) |
| NCT04152200 | A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 | Phase 3 | Completed | Jan 21, 2020 | May 18, 2021 (actual) |
| NCT05761301 | A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM | 1 | Terminated | Mar 10, 2023 | Apr 3, 2025 (actual) |
| NCT03905694 | A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1 | Phase 3 | Completed | Apr 22, 2019 | Jun 29, 2020 (actual) |
| NCT03681184 | A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1 | Phase 3 | Completed | Nov 27, 2018 | Nov 5, 2019 (actual) |
| NCT03841448 | A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN) | Phase 2 | Terminated | Sep 30, 2019 | Mar 17, 2022 (actual) |
| NCT05161936 | A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels | Phase 2 | Terminated | Jan 27, 2022 | Nov 1, 2022 (actual) |
| NCT04056481 | Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria | Not listed | Approved for marketing | Not listed | Not listed |
| NCT02939820 | Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR) | Not listed | Approved for marketing | Not listed | Not listed |
| NCT04565717 | A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) | Phase 1 | Terminated | Oct 9, 2020 | Jan 6, 2023 (actual) |
| NCT03350451 | An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1 | Phase 2 | Completed | Apr 4, 2018 | Feb 7, 2023 (actual) |
| NCT03338816 | ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP) | Phase 3 | Completed | Nov 16, 2017 | Jan 31, 2019 (actual) |
| NCT01960348 | APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis | Phase 3 | Completed | 2013-11 | 2017-08 (actual) |
| NCT03862807 | Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant | Phase 3 | Completed | Mar 27, 2019 | Oct 6, 2020 (actual) |
| NCT01617967 | Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis | Phase 2 | Completed | 2012-05 | 2013-10 (actual) |
| NCT01961921 | The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran) | Phase 2 | Completed | 2013-10 | 2016-07 (actual) |
| NCT05256810 | A Study to Evaluate ALN-XDH in Healthy Subjects and Patients With Gout | Phase 1/Phase 2 | Terminated | Feb 25, 2022 | Jan 25, 2023 (actual) |
FDA records (last 2 years)
- FDA New indication / efficacy supplement: AMVUTTRA (vutrisiran sodium) — NDA215515/6, Mar 20, 2025. Applicant at approval: Alnylam Pharmaceuticals, Inc. source ↗
NIH awards 3
- NIH contract (government contract; not a grant and not an investment round) N01AI60012-3-0-1 FY2009: $1,228,477 awarded for that fiscal year; activity N01 (OTHER_NIH); PI DE FOUGEROLLES, TONY; recipient as written: ALNYLAM PHARMACEUTICALS, CAMBRIDGE, MA. Broad source ↗
- NIH contract (government contract; not a grant and not an investment round) N01AI60012-2-0-1 FY2008: $7,547,998 awarded for that fiscal year; activity N01 (OTHER_NIH); PI n/a; recipient as written: ALNYLAM PHARMACEUTICALS, CAMBRIDGE, MA. Broad Spectrum RNAi An source ↗
- NIH award 1R43AI069612-01 FY2006: $590,073 awarded for that fiscal year; activity R43 (SBIR); PI DEFOUGEROLLES, ANTONIN; recipient as written: ALNYLAM PHARMACEUTICALS, CAMBRIDGE, MA. siRNA Intervention Strategies for source ↗
Raises and investors new
- InvestorListed in the portfolio of ARCH Venture Partners (captured Oct 12, 2026). portfolio page ↗
- InvestorListed in the portfolio of Atlas Venture (captured Oct 12, 2026). portfolio page ↗
Open jobs 115
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| Senior Manager, HCP Marketing, US Congress Lead | United States | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Principal Scientist, Biotransformation and Metabolite Profiling | United States | Oct 21, 2026 | Oct 22, 2026 | Not stated |
| Senior Director, Commercial Operations | Cambridge, MA | Oct 21, 2026 | Oct 22, 2026 | Not stated |
| Manager, Global Patient Safety & Risk Mgmnt | Cambridge, MA | Oct 16, 2026 | Oct 17, 2026 | Not stated |
| Associate Director, Identity & Access Management Architect | Cambridge, MA | Oct 15, 2026 | Oct 16, 2026 | Not stated |
| Area Sales Manager, Northeast Germany | Germany | Oct 15, 2026 | Oct 16, 2026 | Not stated |
| Senior Director, Toxicology | United States | Oct 15, 2026 | Oct 16, 2026 | Not stated |
| Vice President, Early Pipeline Delivery | United States | Oct 14, 2026 | Oct 15, 2026 | Executive |
| Associate Director, Program Management | Cambridge, MA | Oct 14, 2026 | Oct 15, 2026 | Senior |
| Associate Scientist II, Bioanalytical Sciences | Cambridge, MA | Oct 13, 2026 | Oct 14, 2026 | Mid |
| Clinical Operations & Regulatory Placement Student | Maidenhead, United Kingdom | Oct 12, 2026 | Oct 14, 2026 | Entry |
| Medical & Commercial Placement Student | Maidenhead, United Kingdom | Oct 12, 2026 | Oct 14, 2026 | Entry |
| Sr Director, IT - Ethics, Compliance & Legal Technology | Cambridge, MA | Oct 9, 2026 | Oct 12, 2026 | Senior |
| Submit Your Resume for Future Opportunities at Alnylam's Norton Manufacturing Site | Norton MA | Oct 9, 2026 | Oct 12, 2026 | Not stated |
| Director, Product Development | Cambridge, MA | Oct 9, 2026 | Oct 12, 2026 | Senior |
| Regional Business Director, TTR - South Central (Atlanta, AL, LA, AR, MS) | United States | Oct 8, 2026 | Oct 12, 2026 | Senior |
| Business Account Executive, TTR - Orlando, FL | United States | Oct 8, 2026 | Oct 12, 2026 | Mid |
| Business Account Executive, Rare Disease - Upstate New York | United States | Oct 8, 2026 | Oct 12, 2026 | Mid |
| Sr. Manager, Medical Science Liaison - Community, Pacific West (CA, WA, OR, HI, AK, ID, NV, UT, MT) | United States | Oct 8, 2026 | Oct 12, 2026 | Senior |
| Associate Director, Regulatory & Pharmaceutical Affairs (Chief Pharmaceutical Officer Deputy) | Paris, France | Oct 7, 2026 | Oct 12, 2026 | Executive |
| Associate Director of Marketing, KOL Engagement and Enablement | United States | Oct 6, 2026 | Oct 12, 2026 | Senior |
| Senior Director, US Strategic Accounts | United States | Oct 6, 2026 | Oct 12, 2026 | Senior |
| Lead Manufacturing Technician | Norton, MA | Oct 6, 2026 | Oct 12, 2026 | Senior |
| Field Reimbursement Manager - Great Lakes North | Minneapolis, MN, St. Paul, MN, Madison, WI, Milwaukee, WI | Oct 6, 2026 | Oct 12, 2026 | Mid |
| Sr. Director, HCP TTR Marketing | Cambridge, Massachusetts | Oct 5, 2026 | Oct 12, 2026 | Senior |
| Sr. Manager, Clinical Operations | United States | Oct 5, 2026 | Oct 12, 2026 | Senior |
| Director, Global Market Access | Cambridge, Massachusetts | Oct 2, 2026 | Oct 12, 2026 | Senior |
| Associate Director, Commercial Consent, Identity & Preference Management | Cambridge, MA | Oct 2, 2026 | Oct 12, 2026 | Senior |
| Quality Control Analyst III | Norton, MA | Oct 1, 2026 | Oct 12, 2026 | Mid |
| VP, Global Trial Optimization | Cambridge, MA | Oct 1, 2026 | Oct 12, 2026 | Executive |
| VP, Strategic Planning | Cambridge, MA | Oct 1, 2026 | Oct 12, 2026 | Executive |
| Associate Director, Clinical Pharmacology | United States | Sep 30, 2026 | Oct 12, 2026 | Senior |
| Director, Regulatory Affairs, Global Labeling Strategy (US) | United States | Sep 30, 2026 | Oct 12, 2026 | Senior |
| Scientist, Biocatalysis & Protein Engineering | Cambridge, MA | Sep 29, 2026 | Oct 12, 2026 | Senior |
| Senior Director, Global Environmental Health, Safety and Sustainability | Cambridge, MA | Sep 29, 2026 | Oct 12, 2026 | Senior |
| Associate Director, Commercial Technology & Data Engineering | Cambridge, MA | Sep 29, 2026 | Oct 12, 2026 | Senior |
| Associate Medical Director, Global Safety Medical Review | United States | Sep 29, 2026 | Oct 12, 2026 | Senior |
| Senior Director, Global Pharmacovigilance Quality Assurance Lead | Cambridge, MA; Philadelphia, PA; Virtual | Sep 28, 2026 | Oct 12, 2026 | Senior |
| Sr. Manager, Clinical Operations | Maidenhead, UK | Sep 28, 2026 | Oct 12, 2026 | Senior |
| Director, Digital HR Platforms | Cambridge, MA | Sep 25, 2026 | Oct 12, 2026 | Senior |
| Associate Director, Scientific Communications Strategy & Excellence | United States | Sep 24, 2026 | Oct 12, 2026 | Senior |
| Director, Regulatory Technology | Cambridge, MA | Sep 24, 2026 | Oct 12, 2026 | Senior |
| Quality Control Analyst II-Weekend Shift | Norton, MA | Sep 23, 2026 | Oct 12, 2026 | Mid |
| Key Account Manager, Barcelona | Barcelona, Spain | Sep 23, 2026 | Oct 12, 2026 | Mid |
| Field Reimbursement Manager - Northwest | Seattle, Washington, United States | Sep 22, 2026 | Oct 12, 2026 | Mid |
| Sr. Manager, Regulatory Affairs | Maidenhead, United Kingdom | Sep 22, 2026 | Oct 12, 2026 | Senior |
| Director, Platform Infrastructure | Cambridge, MA | Sep 21, 2026 | Oct 12, 2026 | Senior |
| Associate Director, Regulatory Strategy | Maidenhead, United Kingdom | Sep 21, 2026 | Oct 12, 2026 | Senior |
| Associate Director, Cyber Defense - Staff Incident Responder | Cambridge, MA | Sep 21, 2026 | Oct 12, 2026 | Senior |
| Director, Ethics and Compliance, AI & Technology Governance | Cambridge, MA | Sep 17, 2026 | Oct 12, 2026 | Senior |
Connect
See your connections at Alnylam Pharmaceuticals on LinkedIn (search by name, results not checked)